We are live on ! Find out more
Alyeska Investment Group

Alyeska Investment Group Portfolio holdings

AUM $35.4B
1-Year Est. Return 33.54%
This Fund
S&P 500
This Quarter Est. Return
+8.11%
1 Year Est. Return
+33.54%
3 Year Est. Return
+101.08%
5 Year Est. Return
+102.29%
10 Year Est. Return
+544.32%
AUM
$12.6B
AUM Growth
-$813M
Cap. Flow
-$1.34B
Cap. Flow %
-10.62%
Top 10 Hldgs %
15.55%
Holding
605
New
149
Increased
96
Reduced
113
Closed
185

Top Buys

Rank Stock Value
1
IBM icon
IBM
IBM
+$269M
2
GE icon
GE Aerospace
GE
+$170M
3
ADI icon
Analog Devices
ADI
+$142M
4
KEY icon
KeyCorp
KEY
+$122M
5
MSI icon
Motorola Solutions
MSI
+$108M

Top Sells

Rank Stock Value
1
TXN icon
Texas Instruments
TXN
+$213M
2
GGP
GGP Inc.
GGP
+$153M
3
GD icon
General Dynamics
GD
+$143M
4
ZBH icon
Zimmer Biomet
ZBH
+$119M
5
EQIX icon
Equinix
EQIX
+$104M

Sector Composition

Rank Sector Weight
1 Technology 17.04%
2 Industrials 16.34%
3 Healthcare 11.75%
4 Consumer Discretionary 11.52%
5 Financials 10.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGS
401
CALL
DELISTED
Argos Therapeutics, Inc.
ARGS
$600K ﹤0.01%
10,000
– –
NTBL
402
CALL
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$592K ﹤0.01%
2,381
– –
KA
403
DELISTED
Kineta, Inc. Common Stock
KA
$583K ﹤0.01%
+714
New +$274K
INO icon
404
Inovio Pharmaceuticals
INO
$69.6M
$581K ﹤0.01%
11,727
– –
ANTH
405
CALL
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$571K ﹤0.01%
+346,011
New +$595K
PTLA
406
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$565K ﹤0.01%
11,600
– –
SLS icon
407
CALL
SELLAS Life Sciences
SLS
$2.3B
$556K ﹤0.01%
47
-6
-11% -$2.9K
SMMT icon
408
Summit Therapeutics
SMMT
$10.8B
$554K ﹤0.01%
50,000
– –
NERV icon
409
Minerva Neurosciences
NERV
$207M
$496K ﹤0.01%
10,239
– –
XFOR icon
410
X4 Pharmaceuticals
XFOR
$393M
$460K ﹤0.01%
+200
New +$506K
ALTR
411
DELISTED
Altair Engineering Inc
ALTR
$459K ﹤0.01%
+19,202
New +$427K
CXT icon
412
Crane NXT
CXT
$3.13B
$370K ﹤0.01%
+11,925
New +$349K
TNDM icon
413
Tandem Diabetes Care
TNDM
$1.29B
$329K ﹤0.01%
+139,196
New +$437K
TCON
414
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$327K ﹤0.01%
488
– –
ATXS
415
DELISTED
Astria Therapeutics
ATXS
$326K ﹤0.01%
3,645
– –
CHKP icon
416
Check Point Software Technologies
CHKP
$12.8B
$298K ﹤0.01%
+2,872
New +$312K
VLRX
417
DELISTED
VALERITAS HOLDINGS INC
VLRX
$250K ﹤0.01%
4,393
-2,692
-38% -$173K
NVCN
418
DELISTED
Neovasc Inc.
NVCN
$66K ﹤0.01%
4
-15
-79% -$413K
GEVO icon
419
CALL
Gevo
GEVO
$351M
$57K ﹤0.01%
4,852
– –
TBCH
420
Turtle Beach Corp
TBCH
$249M
$49K ﹤0.01%
27,122
-85,302
-76% -$210K
AAL icon
421
American Airlines Group
AAL
$10.6B
– –
-50,723
Closed -$2.41M
ABBV icon
422
AbbVie
ABBV
$431B
– –
-19,294
Closed -$1.71M
ABR icon
423
Arbor Realty Trust
ABR
$957M
– –
-533,178
Closed -$4.37M
ACN icon
424
Accenture
ACN
$105B
– –
-146,288
Closed -$19.8M
AGO icon
425
Assured Guaranty
AGO
$3.66B
– –
-25,861
Closed -$976K
15 16
17
18 19

Similar funds

Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
SAM
Storebrand Asset Management Lysaker, Norway $34.8B AUM 25.49% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
MML Investors Services
MML Investors Services Springfield, Massachusetts $36.1B AUM 19.68% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
VIA
Vanguard Investments Australia Victoria, Australia $34.6B AUM

Alyeska Investment Group's Q4 2017 Portfolio in Review

As of Q4 2017, Alyeska Investment Group held 605 positions worth $12.6B, down 6.1% from $13.4B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Alyeska Investment Group withdrew a net $1.34B in Q4 2017, closing 185 positions and reducing 113 holdings. Its most notable exit was Texas Instruments, an estimated $213M position sold in full.

By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 17% a quarter earlier, followed by Industrials and Healthcare.

Against the trend, Alyeska Investment Group opened a new position in IBM worth $272M.

  • Alyeska Investment Group's largest Q4 2017 buy was IBM: 1,851,994 shares worth $272M.
  • Alyeska Investment Group added most to KeyCorp in Q4 2017, an estimated $122M increase.
  • Alyeska Investment Group's biggest Q4 2017 reduction was Equinix, cutting an estimated $104M.
  • Alyeska Investment Group fully exited Texas Instruments in Q4 2017, selling an estimated $213M.
  • Alyeska Investment Group's ten largest holdings make up 16% of its $12.6B portfolio in Q4 2017.
  • Alyeska Investment Group opened 149 new positions and closed 185 in Q4 2017.
  • Alyeska Investment Group's portfolio value fell 6.1% quarter-over-quarter to $12.6B.

Based on Alyeska Investment Group's 13F filing for Q4 2017, filed 14 Feb 2018.